Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study With Aminophylline to Attenuate of the Side Effects of Regadenoson
NCT01250496 · Rush University Medical Center · PHASE4 · terminated · last registry update 2023-03-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Due to nationwide shortage of Aminophylline. Enrolled subjects did not complete study.” | – | Registry record, Rush University Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDE4A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-01-17Results posted on the registry: University of Michigan, Amlexanox (NCT01842282)
- 2024-01-11Also stopped (terminated): Baylor College of Medicine, Pentoxifylline (NCT01774487)
- 2024-01-09Phase 3 first posted: Mahidol University, Aminophylline (NCT06196853)
- 2024-01-09Results posted on the registry: Massachusetts General Hospital, Theophylline (NCT02479451)
- 2024-01-05Results posted on the registry: Amgen, Apremilast (CC-10004) (NCT03747939)
- 2023-12-07Results posted on the registry: Amgen, Apremilast (CC-10004) (NCT03701763)
- 2023-11-13Results posted on the registry: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA, Ensifentrine + Placebo (NCT04535986)
- 2023-11-08Phase 3 first posted: Amgen, apremilast + Placebo (NCT06122649)
- 2023-11-07Also stopped (terminated): Clear Creek Bio, Inc., Brequinar Sodium + Dipyridamole 75 MG (NCT05166876)
- 2023-11-07Results posted on the registry: Icahn School of Medicine at Mount Sinai, Apremilast + Placebo (NCT02684123)
- 2023-10-31Phase 3 first posted: Takeda, TAK-279 + Placebo (NCT06108544)
- 2023-10-18Phase 3 first posted: Amgen, Apremilast (NCT06088199)
- 2023-10-18Phase 3 first posted: Takeda, TAK-279 + Placebo (NCT06088043)
- 2023-10-16Phase 3 first posted: Humanis Saglık Anonim Sirketi, Apremilast 30 mg Tablets + Otezla 30 mg film-coated tablets (NCT06084663)
- 2023-10-12Results posted on the registry: Baylor College of Medicine, Pentoxifylline (NCT01774487)
- 2023-10-04Also stopped (terminated): Legacy Health System, Trental Pill (NCT03916068)
- 2023-09-26Phase 3 first posted: Sunnybrook Health Sciences Centre, modified PENTOCLO (mPENTOCLO) + sham mPENTOCLO (NCT06055257)
- 2023-09-15Phase 3 first posted: University of Brasilia, Miltefosine 50mg + Pentoxifylline 400mg (NCT06040489)
- 2023-09-14Results posted on the registry: University of Cincinnati, Trental (NCT01508221)
- 2023-08-31Results posted on the registry: Boehringer Ingelheim, EU-sourced Otezla® + US-sourced Otezla® (NCT04811573)
- 2023-08-31Also stopped (terminated): Boehringer Ingelheim, EU-sourced Otezla® + US-sourced Otezla® (NCT04811573)
- 2023-08-02Phase 3 first posted: Beni-Suef University, tadalafil + Sildenafil (NCT05971667)
- 2023-07-24Results posted on the registry: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA, Ensifentrine + Placebo (NCT04542057)
- 2023-07-12Results posted on the registry: GE Healthcare, PET MPI + SPECT MPI (NCT03354273)
- 2023-07-06Phase 3 first posted: University of Malaya, Aminophylline + Frusemide (NCT05933642)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision